Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Biodistribution of 111In-DOTA-h11B6 in mCRPC
NCT04116164Phase 1Terminated
- Sponsor
- SpectronRx
- Start
- Sep 2019
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of h11B6 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by SpectronRx. Primary endpoints: Serum pharmacokinetics at 6 months, Radioactivity Biodistribution at 6 months and 1 more. Started Sep 2019; status: terminated.
02
Drugs
h11B6
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04116164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04116164.